Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. — CFSMEATLAS
Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients.
Eaton-Fitch, Natalie, Du Preez, Stanley, Cabanas, Hélène et al. · Journal of translational medicine · 2022 · DOI
Quick Summary
This study found that immune cells called natural killer cells in ME/CFS patients have a broken calcium channel (TRPM3) that prevents them from working properly. When researchers treated these cells overnight with a drug called naltrexone, the calcium channel started working better and the immune cells functioned more like those from healthy people. This suggests that ME/CFS may involve faulty ion channels and that naltrexone could potentially help restore immune cell function.
Why It Matters
This research provides mechanistic evidence that ME/CFS involves defective ion channel function in immune cells, which could explain the persistent immune dysfunction observed in patients. The finding that naltrexone can restore calcium signaling in vitro offers a potential therapeutic target and may explain clinical observations of naltrexone benefits in some ME/CFS patients.
Observed Findings
ME/CFS patients' NK cells showed significantly reduced calcium influx amplitude compared to healthy controls at baseline (p<0.0001).
ME/CFS patients' NK cells showed significantly prolonged half-time of calcium response compared to healthy controls at baseline (p<0.0001).
Overnight naltrexone treatment significantly increased calcium influx amplitude in ME/CFS patients' NK cells (p<0.0001).
After naltrexone treatment, there was no significant difference in calcium response kinetics between ME/CFS patients and healthy controls.
Inferred Conclusions
TRPM3 loss of function results in impaired calcium influx in NK cells of ME/CFS patients, supporting the hypothesis that ME/CFS is a TRP ion channel disorder.
Naltrexone restores TRPM3-dependent calcium signaling in ME/CFS NK cells to near-normal levels.
Naltrexone may represent a potential therapeutic intervention for ME/CFS by antagonizing µ-opioid receptor inhibition of TRPM3.
Remaining Questions
Does naltrexone treatment improve NK cell cytotoxic function and clinical symptoms in ME/CFS patients in vivo?
Are there other ion channels besides TRPM3 that are dysfunctional in ME/CFS, and do they contribute additively to disease pathology?
What This Study Does Not Prove
This study does not prove that naltrexone will be clinically effective in ME/CFS patients in real-world conditions—only that it works in isolated cells in a lab dish. The findings do not establish that TRPM3 dysfunction is the sole cause of ME/CFS or that restoring calcium influx will fully reverse disease symptoms. It also does not address whether other ion channels or cellular mechanisms contribute to ME/CFS pathology.